Description
Indication & Scope
BangRuiShun (Bezacitinib) is a domestically developed selective JAK2 inhibitor indicated for adult patients with intermediate-2 or high-risk myelofibrosis. By targeting JAK2-mediated signaling pathways, Bezacitinib helps reduce disease-related splenomegaly and improve myelofibrosis-associated symptoms.
- Mechanism: Bezacitinib selectively inhibits Janus kinase 2 (JAK2) signaling, including pathways associated with JAK2 V617F mutation, reducing abnormal cytokine signaling involved in myeloproliferative neoplasm progression.
- Drug class: Selective Janus kinase 2 (JAK2) inhibitor.
- Clinical use: Treatment of adult patients with intermediate-2 or high-risk PMF, PPV-MF, or PET-MF.
| Generic Name | Bezacitinib |
| Brand Name | BangRuiShun® |
| Ingredient | Each tablet contains bezacitinib. |
| Dosage Form | Film-coated Tablet |
| Package | 4 mg × 1 tablet; 16 mg × 1 tablet |
| Conditions Treated | Adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis. |
| Taboos | Hypersensitivity to bezacitinib or any component of the product. |
| Place of origin | China |
| Prescription type | Prescription Drug (Rx) |
| Storage Conditions | Refer to the approved package labeling. |
| Manufacturer | Hangzhou Bangshun Pharmaceutical Co., Ltd. |
| Registration Authority | National Medical Products Administration (NMPA), China |
| Approval number | H20260021 |
| Date of Revision | 2026 |
| Shelf Life | Refer to the approved package labeling |
How to use ?
Recommended Dose: 20 mg administered orally twice daily according to the approved prescribing information.
Time: Administer twice daily following the approved dosing schedule.
Instructions for use: Take orally as directed by a healthcare professional. Dose adjustments may be required according to hematologic parameters, tolerability, and clinical response.
Interaction: Bezacitinib has a low potential for CYP-mediated drug interactions based on its metabolic characteristics.
Side effects: Common adverse reactions may include anemia, thrombocytopenia, neutropenia, infections, increased serum creatinine, diarrhea, and hypertension.
Important Notice
This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What is BangRuiShun (Bezacitinib) used for?
It is used for adult patients with intermediate-2 or high-risk myelofibrosis, including PMF, PPV-MF, and PET-MF.
How does it work?
It inhibits JAK2 signaling pathways involved in myelofibrosis progression.
What are the common adverse reactions?
Common adverse reactions include blood count abnormalities, infection-related events, gastrointestinal reactions, and laboratory abnormalities.
Is it a chemotherapy drug?
No. It is a targeted JAK2 inhibitor.
BangRuiShun® Bezacitinib | Myelofibrosis Treatment | DengYueRX
INN: Bezacitinib
Indications: Intermediate-2 or high-risk myelofibrosis
Dosage Form: Film-coated Tablet
Strength: 4 mg; 16 mg
